Kathleen ME Gallagher
My principal interest is in the development of assays for the characterization and monitoring of immune responses to immunotherapeutic treatments in patients with cancer. The Immune Monitoring Laboratory in MGH focuses on the provision of a high quality service to support clinical trials performed at Mass General Hospital, with a particular focus on CAR-T therapies. In my previous role in the UK, I directed an ISO-15189 accredited immunophenotyping referral service in Birmingham University. In addition to routine flow cytometry for diagnosis and monitoring of hematological malignancies and immunodeficiencies, we also validated a sensitive flow measurable residual disease (MRD) assay for the NCRI AM18 and AML19 MRD trials. I was responsible for overseeing processing and analysis of over 2,000 patient samples from both national and international sites. Prior to my role as a clinical scientist, my PhD and post-doctoral roles focused on anti-viral T cell and NK immune responses in patients with chronic viral infections. My career goal is to help to improve patient outcomes and personalized treatments in order to maximize efficacy and minimize treatment-related toxicity.
Abstracts this author is presenting: